science_tech
Do mRNA tumour vaccines herald a new revolution in cancer treatment?
Results of a recent melanoma trial using mRNA vaccines have been exciting. If the promise of mRNA tumour vaccines holds across multiple cancers, then this could be the next great leap forward in cancer care
Context
Recent clinical trials, specifically the Phase III INTerpath-001 trial, have demonstrated the efficacy of personalised mRNA tumour vaccines in treating high-risk melanoma. These therapeutic vaccines, customised using a patient's unique genetic tumour profile, represent a significant advancement in oncology, shifting the paradigm from targeted therapy to highly precise, individualised immunotherapy.
Exam Perspectives
Key References
AI-generated study notes · sourced from The Hindu